Role of traditional risk factors and antiretroviral drugs in the incidence of chronic kidney disease, ANRS CO3 Aquitaine cohort, France, 2004-2012
about
Raltegravir non-inferior to nucleoside based regimens in second-line therapy with lopinavir/ritonavir over 96 weeks: a randomised open label study for the treatment of HIV-1 infectionLong-term efficacy and toxicity of abacavir/lamivudine/nevirapine compared to the most prescribed ARV regimens before 2013 in a French Nationwide Cohort Study.Antiretroviral therapy: current drugsA chronic kidney disease risk score to determine tenofovir safety in a prospective cohort of HIV-positive male veterans.Protease Inhibitors and Renal Function in Patients with HIV Infection: a Systematic Review.Hepatitis C co-infection is associated with an increased risk of incident chronic kidney disease in HIV-infected patients initiating combination antiretroviral therapy.Switching to Tenofovir Alafenamide, Coformulated With Elvitegravir, Cobicistat, and Emtricitabine, in HIV-Infected Patients With Renal Impairment: 48-Week Results From a Single-Arm, Multicenter, Open-Label Phase 3 StudyEffect of Tenofovir Disoproxil Fumarate on Incidence of Chronic Kidney Disease and Rate of Estimated Glomerular Filtration Rate Decrement in HIV-1-Infected Treatment-Naïve Asian Patients: Results from 12-Year Observational Cohort.Organ Transplantation in HIV Patients: Current Status and New Directions.Integrase inhibitor versus protease inhibitor based regimen for HIV-1 infected women (WAVES): a randomised, controlled, double-blind, phase 3 study.Impact of age on care pathways of people living with HIV followed up in hospital.Antiretroviral resistance at virological failure in the NEAT 001/ANRS 143 trial: raltegravir plus darunavir/ritonavir or tenofovir/emtricitabine plus darunavir/ritonavir as first-line ART.A multifaceted intervention designed to improve medical management of moderate to advanced chronic kidney disease in HIV-infected patients: a cluster randomized trial.A week 48 randomized phase 3 trial of darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naïve HIV-1 patients.Racial disparities in the prevalence and control of hypertension among a cohort of HIV-infected patients in the southeastern United States.Absence of Decline of Kidney Function in Human Immunodeficiency Virus-Infected Patients Under Routine Clinical Management.
P2860
Q28543732-78C4C397-B328-44A3-B28D-0F0C2B8B6D52Q33595432-8763A07E-9269-47D9-9A92-EA0F9927870BQ34085926-E5E1332A-20C4-4730-AEA0-46EFFAED4F9BQ34301401-5DD88ABD-5FA0-4725-8731-E4AC1F60CAF6Q35186842-556EB769-4BB5-46C6-AC91-D58A0D6C42A9Q36334834-493D38E2-0C19-4CBF-BB90-0B22331A2CFAQ36721012-4BA9BC1A-626A-4C11-A6F1-623E61D55979Q37713060-40C77ED1-49DC-4194-9AC9-10FDEF91EACBQ38154230-071EE17B-031A-48AF-ABA9-4D6939626781Q38853255-1984FDC5-4CCA-4EEB-8C80-C780075C5BA7Q39661882-5010D41F-E81E-4020-975E-1D0B83808CE2Q40857943-1ABEBE1B-F31E-4D58-A8CF-30E0D0690A92Q41294510-C839F089-4204-4283-A4DC-81CD2C2476B0Q52570173-8AF8BC9C-393F-46C4-B260-2A3DA81FCE6DQ52622040-5EFA14D5-0730-4ED7-8FB2-23DA924B58FDQ54399765-2FEC6D58-C089-4F6C-B12C-F717E50478CE
P2860
Role of traditional risk factors and antiretroviral drugs in the incidence of chronic kidney disease, ANRS CO3 Aquitaine cohort, France, 2004-2012
description
2013 nî lūn-bûn
@nan
2013 թուականին հրատարակուած գիտական յօդուած
@hyw
2013 թվականին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Role of traditional risk facto ...... aine cohort, France, 2004-2012
@ast
Role of traditional risk facto ...... aine cohort, France, 2004-2012
@en
Role of traditional risk facto ...... aine cohort, France, 2004-2012
@nl
type
label
Role of traditional risk facto ...... aine cohort, France, 2004-2012
@ast
Role of traditional risk facto ...... aine cohort, France, 2004-2012
@en
Role of traditional risk facto ...... aine cohort, France, 2004-2012
@nl
prefLabel
Role of traditional risk facto ...... aine cohort, France, 2004-2012
@ast
Role of traditional risk facto ...... aine cohort, France, 2004-2012
@en
Role of traditional risk facto ...... aine cohort, France, 2004-2012
@nl
P2093
P2860
P1433
P1476
Role of traditional risk facto ...... aine cohort, France, 2004-2012
@en
P2093
Didier Neau
Edouard Déti
Estibaliz Lazaro
Fabrice Bonnet
Frédéric-Antoine Dauchy
Julien Asselineau
Marie-Anne Vandenhende
Philippe Morlat
Pierre Duffau
Yann Gerard
P2860
P304
P356
10.1371/JOURNAL.PONE.0066223
P407
P577
2013-01-01T00:00:00Z